 |
|
Best use of drug-eluting stents
September 02, 2008When should they be avoided?
Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. The use of drug-eluting stents necessitates extended treatment with dual antiplatelet therapy (aspirin plus thienopyridine) which may cause bleeding complications and interferes with or even precludes surgery in case this is needed.
In addition, from a socioeconomic standpoint, the increased cost associated with drug-eluting stents is a major issue.
Based on these considerations, drug-eluting stents should be avoided (a) when the expected benefit is low and (b) when the risk associated with extended dual antiplatelet therapy is high.
After placement of bare metal stents, the risk of restenosis varies considerably based on patient and lesion characteristics. Specifically, patients who do not suffer from diabetes have a substantially lower risk than diabetic patients. Strong lesion-specific predictors of a low risk of restenosis after bare metal stents include short lesion length and large vessel size. Thus, in non-diabetic patients with a short lesion in a large vessel, the risk of restenosis after placement of a bare metal stent is below 10 %. In these subsets, a substantial benefit from drug-eluting stents cannot be expected. These considerations are confirmed by data from randomized studies as well as from registries.
In patients with bleeding disorders, the risk of bleeding complications during dual antiplatelet therapy is particularly high. On the other hand, premature discontinuation of dual antiplatelet therapy for imminent or overt bleeding carries a substantial risk of stent thrombosis with potentially fatal outcome. A particularly difficult patient subset in this respect concerns those in need for anticoagulation, such as patients with atrial fibrillation at high risk for thromboembolic events or patients with prosthetic valve replacement. In these patients, interventional cardiologists are well advised to use a bare metal stent to keep the need for dual antiplatelet therapy as short as possible.
Drug-eluting stents should also be avoided in patients with planned surgical procedure and in those likely to undergo a surgery within the next year.
European Society of Cardiology
Based on these considerations, drug-eluting stents should be avoided (a) when the expected benefit is low and (b) when the risk associated with extended dual antiplatelet therapy is high.
After placement of bare metal stents, the risk of restenosis varies considerably based on patient and lesion characteristics. Specifically, patients who do not suffer from diabetes have a substantially lower risk than diabetic patients. Strong lesion-specific predictors of a low risk of restenosis after bare metal stents include short lesion length and large vessel size. Thus, in non-diabetic patients with a short lesion in a large vessel, the risk of restenosis after placement of a bare metal stent is below 10 %. In these subsets, a substantial benefit from drug-eluting stents cannot be expected. These considerations are confirmed by data from randomized studies as well as from registries.
In patients with bleeding disorders, the risk of bleeding complications during dual antiplatelet therapy is particularly high. On the other hand, premature discontinuation of dual antiplatelet therapy for imminent or overt bleeding carries a substantial risk of stent thrombosis with potentially fatal outcome. A particularly difficult patient subset in this respect concerns those in need for anticoagulation, such as patients with atrial fibrillation at high risk for thromboembolic events or patients with prosthetic valve replacement. In these patients, interventional cardiologists are well advised to use a bare metal stent to keep the need for dual antiplatelet therapy as short as possible.
Drug-eluting stents should also be avoided in patients with planned surgical procedure and in those likely to undergo a surgery within the next year.
European Society of Cardiology
Antiplatelet Therapy Current Events and Antiplatelet Therapy News RSSAspirin works for primary prevention in moderate and high risk diabetics
The beneficial effects of aspirin in primary prevention of cardiovascular events i.e. stroke, MI and cardiac death are known and generally accepted.
Genetic variation associated with poorer response, cardiovascular outcomes with use of clopidogrel
Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.
Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
The Cardiovascular Research Foundation (CRF) announced that results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) were published online June 15 in the journal Circulation.
New tool calculates risk of bleeding in heart attack patients
With eight basic medical facts in hand, doctors can now estimate the risk of bleeding for a patient having a heart attack.
Triple antiplatelet therapy appears superior to dual antiplatelet therapy
Results of five research studies and a clinical registry first-report presentation scheduled for the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggest that triple antiplatelet therapy for patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents achieves greater platelet inhibition than conventional dual antiplatelet therapy.
Study Finds Half of Patients Undergoing Cerebrovascular Stent Placement Respond Poorly to the Antiplatelet Drug Clopidogrel (Plavix)
A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent placement did not respond well to clopidogrel. Clopidogrel (Plavix) and aspirin are medications routinely prescribed for 1-3 months following cerebrovascular stent placement to combat the risk of blood clots (stent-thrombosis) and reclosure of the artery (re-stenosis).
Increased risk of heart attack or stroke for patients who are resistant to aspirin
Being resistant to aspirin makes patients four times more likely to suffer a heart attack, stroke or even die from a pre-existing heart condition, according to a study published on bmj.com today.
Value of stent-coating drugs questioned
Patients admitted to the hospital with acute coronary syndromes (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention (PCI), during which a stent is inserted into an occluded or narrowed coronary artery to restore blood flow to and from the heart.
Patients who receive drug-eluting stents should continue antiplatelet medications
Patients who have had drug-eluting stents inserted to prop open blocked coronary arteries should continue to take medications to reduce the risk of blood clots for at least one year after the stent is inserted, a new scientific advisory recommends.
New generation of cardiac interventions, therapies optimize heart disease care
Research presented today at the American College of Cardiology's 55th Annual Scientific Session and the inaugural Innovation in Intervention: i2 Summit 2006 in Atlanta, Ga., highlights critical advances in the treatment of cardiovascular disease.
More Antiplatelet Therapy Current Events and Antiplatelet Therapy News Articles
 |
Antiplatelet Therapy In Ischemic Heart Disease (American Heart Association Clinical Series) by Stephen D. Wiviott (Author) * Draws from expertise of leaders in antiplatelet therapy * Easy-to-use layout enables rapid browsing * Edited by a member of the prestigious TIMI study group with long-standing experience in the field |
 |
Preventing Ischemic Events: Advances in Antiplatelet Therapy (NCME Video 733) Also With: Network For Continuing Medical Education (Primary Contributor), Alan T. Hirsch (Primary Contributor), Eric C. Ras (Primary Contributor), Eric J. Topol (Primary Contributor) Atherosclerosis is a systemic disease that contributes to the death of 500,000 Americans by myocadial infarction and 150,000 Americans by stroke each year. In addition, peripheral arterial disease affects over 7 million Americans, two thirds of whom are undiagnosed. The modification of medical and lifestyle risk factors (e.g. diet, exercise, hypertension, smoking, and diabetes) and the daily administration of aspirin have been shown to save lives. However, aspirin is a relatively weak antiplatelet agent in that it interferes with one of the less significant intracellular processes that cause platelets to bind together. In this video, Drs. Hirsch, Raps, and Topol explore the role of new antiplatelet therapies in myocardial infarction, stroke, and peripheral arterial disease. Insights into... |
|
Triple therapy reduces primary stroke severity: the combination of antiplatelet therapy, statins, and ACE inhibitors also led to better outcomes.(Neurology): An article from: Internal Medicine News by Damian McNamara (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on July 1, 2005. The length of the article is 501 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Triple therapy reduces primary stroke severity: the combination of antiplatelet therapy, statins, and ACE inhibitors also led to better outcomes.(Neurology) Author: Damian McNamara Publication: Internal Medicine News (Magazine/Journal) Date: July 1, 2005 Publisher: Thomson Gale Volume: 38 Issue: 13 Page: 16(1) Distributed by Thomson... | |
 |
Antiplatelet Therapy in Atherothrombosis: Supplement Issue: Cerebrovascular Diseases 2006 by S. Uchiyama (Editor), T. Yamaguchi (Editor) |
|
Dual antiplatelet therapy: is more better?(MINDFUL PRACTICE)(Case study)(Clinical report): An article from: Internal Medicine News by Jon O. Ebbert (Author), Eric G. Tangalos (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on August 15, 2006. The length of the article is 933 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Dual antiplatelet therapy: is more better?(MINDFUL PRACTICE)(Case study)(Clinical report) Author: Jon O. Ebbert Publication: Internal Medicine News (Magazine/Journal) Date: August 15, 2006 Publisher: Thomson Gale Volume: 39 Issue: 16 Page: 39(1) Article Type: Clinical report, Case study Distributed by Thomson... | |
|
Combo first to improve MI mortality in 12 years: dual antiplatelet therapy--aspirin plus a short course of clopidoxrel--shines in two large studies.(Cardiovascular ... An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on April 15, 2005. The length of the article is 1296 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Combo first to improve MI mortality in 12 years: dual antiplatelet therapy--aspirin plus a short course of clopidoxrel--shines in two large studies.(Cardiovascular medicine)(Myocardial Infarction) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 15, 2005 Publisher: International Medical News Group Volume: 35 Issue: 8 ... | |
|
Dual antiplatelet therapy cuts ischemic events. (Clopidogrel Plus Aspirin for 1 Year).: An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2003. The length of the article is 727 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Dual antiplatelet therapy cuts ischemic events. (Clopidogrel Plus Aspirin for 1 Year). Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: January 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 1 Page: 45(1) Distributed by Thomson... | |
|
Antiplatelet therapy is first MI advance in years: combining clopidogrel and aspirin has reduced coronary risk in patients with unstable angina.(Cardiovascular ... An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on May 1, 2005. The length of the article is 1289 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Antiplatelet therapy is first MI advance in years: combining clopidogrel and aspirin has reduced coronary risk in patients with unstable angina.(Cardiovascular Medicine) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: May 1, 2005 Publisher: International Medical News Group Volume: 38 Issue: 9 Page: 62(1) Distributed... | |
|
Antiplatelet Therapy - An Update: 20th Platelet Lake Ashi Conference, Hakone, Japan, October 1999 (Supplement Issue: Haemostasis 2000, Suppl. 3) by Y. Ikeda (Editor) | |
|
Anticoagulants/ Antiplatelet Therapy and Cardiovascular Disease (Cardiology Clinics, 12:3) b |
| © 2009 BrightSurf.com |